Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effectiveness of different anesthetic treatments for patients with glaucoma, a condition that affects the eyes and can lead to vision loss. The study involves patients who have undergone surgery for glaucoma and require a procedure known as needling, which is performed in an outpatient setting. The trial compares two types of anesthetic treatments: a gel containing 2% lidocaine, which is applied to the eye, and eye drops containing a combination of tetracaine and oxybuprocaine.
The purpose of the study is to determine which anesthetic treatment is more effective in reducing pain during the needling procedure. Participants will receive either the lidocaine gel or the tetracaine/oxybuprocaine eye drops before their procedure. The study will measure the level of pain experienced by patients using a simple numerical scale, as well as the time taken to complete the procedure with each type of anesthetic. Additionally, the study will observe if any patients require additional anesthesia or oral pain relief, and assess the comfort of the surgeon and the patient's cooperation during the procedure.
This trial aims to provide valuable information on the best anesthetic approach for patients undergoing needling procedures after glaucoma surgery. By comparing the two treatments, the study seeks to improve patient comfort and surgical outcomes in glaucoma care. The trial is expected to conclude by June 2024, with recruitment starting in November 2023.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
4 criteria
3 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is used as a local anesthetic to numb the surface of the eye. In this clinical trial, it is being tested for its effectiveness in providing pain relief during outpatient glaucoma surgery procedures.
are another type of local anesthetic used to numb the eye. These drops are being compared to lidocaine gel in the trial to see which provides better pain relief during the surgical procedure.
are also used as a local anesthetic for numbing the eye. In this study, they are combined with tetracaine to evaluate their effectiveness in reducing pain during glaucoma surgery.
Lidocaine is administered as a 2% gel applied directly to the eye for local anesthesia. It is widely used in medical practice and literature for its numbing effects, particularly in minor surgical procedures. The main therapeutic indication for lidocaine in this context is to provide anesthesia during glaucoma-related surgeries. At the molecular level, lidocaine works by blocking sodium channels in nerve cells, preventing the transmission of pain signals. It is classified as a local anesthetic.
Tetracaine is used as 0.1% hydrochloride eye drops for local anesthesia, applied directly to the eye. It is well-documented in medical literature for its effectiveness in numbing the eye during procedures. The primary therapeutic use of tetracaine in this trial is to provide anesthesia for patients undergoing glaucoma surgery. Its mechanism of action involves blocking sodium channels in nerve cells, which stops pain signals from being sent to the brain. Tetracaine is classified as a local anesthetic.
Oxybuprocaine is administered as 0.4% hydrochloride eye drops for local anesthesia, applied directly to the eye. It is recognized in medical literature for its use in numbing the eye during various procedures. The main therapeutic indication for oxybuprocaine in this study is to provide anesthesia for glaucoma surgery patients. It works by blocking sodium channels in nerve cells, thereby preventing the transmission of pain signals. Oxybuprocaine is classified as a local anesthetic.
Other trials in this disease – keep exploring while you decide
Spain
DenmarkSpain
FinlandSpainDenmarksourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
